This is what Leslie Chong had to say about the Australian patient enrolments last month,
“We’re proud to be able to bring this trial to Imugene’s home country and provide an opportunity for Australian patients to benefit from this unique technology,” said Imugene’s Managing Director and CEO Leslie Chong. “This is the first of up to five sites we plan to open in Australia, as we seek to speed up enrolment and deliver improved outcomes in this form of blood cancer.”
"The Royal Prince Alfred Hospital in Sydney will begin patient recruitment in November 2024, marking another significant milestone in the development of this promising off-the-shelf allogeneic CAR T cell therapy.
It is all about the clinical trial safety and endpoints in cancer research, where the patients' data for Overall Response Rate % (ORR), Complete Response %(CR), and how long the Durability of Response (DOR) lasts, is submitted to the FDA.
IMO, Cohort B of the study is off to an amazing start.
Regards.
IMU Price at posting:
4.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)